Kornimate/medical-research-clean huggingface dataset:
early palliative care in metastatic esophageal squamous carcinoma (escc) and gastric cancer

Conditions: Metastatic Esophageal Squamous Carcinoma; Gastric Cancer

Summary: the majority of patients with newly diagnosed metastatic escc and gastric cancer patients experience a number of physical and psychosocial symptoms related to their cancer. those patients endure the greatest level of distress from their disease relative to other cancer populations in china. although new drugs have been applied in recent years, the median overall survival time of metastatic escc and gc patients are still around 12 months. therefore, it is essential to maximize their quality of life (qol) from the time of diagnosis. multiple studies demonstrate that symptoms such as pain, fatigue, and anorexia are prevalent at diagnosis and worsen over time. as a result, suffering increases throughout the course of the illness. to be most effective, palliative care with intensive symptom management and psychosocial support should begin at the time of diagnosis, not once life-prolonging therapies have failed. and some studies have revealed that early palliative can even prolong the overall survival time in advanced lung cancer. the investigators then initiated a randomized phase iii clinical trial with standard oncology care plus early palliative care or not in metastatic esophageal carcinoma and gastric cancer to observe whether the early palliative can improve the qol and even prolong the overall survival time in those patients


Eligibility criteria:
inclusion criteria: * having signed informed consent * age ≥18 years old * histologically confirmed esophageal squamous carcinoma and gastric adenocarcinoma, metastatic disease. * measurable disease according to the recist criteria(diameter of the lesion should be more than 10mm by spiral ct or mri, more than 20mm by common ct, the date of image should be less than 15 days before enrollment) * karnofsky performance status ≥80 * life expectancy of ≥ 3 month * wbc \> 3,000/mm3, absolute neutrophil count ≥1500/mm3, platelet \> 100,000/mm3, hb \> 9g/dl(within 14 days before enrollment),alt and ast \< 2.5 times uln (≤5 times uln in patients with liver metastases),bilirubin level \< 1.0 times uln,serum akp \< 2.5 times uln,serum creatinine \< 1.5 times uln * no sever complication, such as active gastrointestinal bleeding, perforation, jaundice, obstruction, non-cancerous fever \> 38℃； * normal ecg and heart function * fertile patients must use effective contraception * good compliance exclusion criteria: * previous treatment of palliative chemotherapy * only with brain or bone metastasis * no measurable lesions, eg. pleural fluid and ascites * suffer from severe heart disease or disease with other important organs * chronic diarrhea or renal dysfunction * pregnancy or lactation period * other previous malignancy within 5 year, except non-melanoma skin cancer chronic diarrhea * mentally abnormal or disable cognition,including cns metastasis
does subspinal le fort i osteotomy affect the nasal airway volume

Conditions: Maxillofacial Abnormalities

Summary: after the description of le fort fractures, maxillary osteotomies are used to correct dentofacial deformities. the profile changes on nasolabial region resulting from a le fort i osteotomy, also that affects nasal airway. the subspinal le fort i osteotomy (slfio) describe to prevent undesirable soft tissue changes. in the literature, too many articles have reported the effectiveness of slfio in preventing nasal deformation. however, there is no study to evaluate the nasal volume or septum deviation.

the purpose of this study was objectively and subjectively to compare the effect of subspinal le fort i osteotomy and conventional le fort i osteotomy on nasal airway volume and septum deviation without additional modification such as ans reduction, alar cinch suture, v-y closure. surgical procedure; patients were underwent general anesthesia for bimaxillary orthognathic surgery. the mucoperiosteal flap was raised to expose the bilateral infraorbital foramina, aperture pyriformis, zygomaticomaxillary, and pterygomaxillary buttress. no dissection was performed between the nasal mucosa and the ans of the patients in subspinal le fort osteotomy group.a triangular osteotomy line was created between the maxilla and the ans with a piezosurgery. in conventional osteotomy group, le fort i osteotomy was made using a piezosurgical saw after nasal mucosa elevation. in both groups, osteotomes and pterygoid plaques, nasal septum, and lateral nasal walls were separated. follow up: septum deviation and nasal. airway volume value was measured and recorded in the cbct images taken before the surgery and at the 6th month after the surgery of each patient.

Eligibility criteria:
inclusion criteria: * aged 18-40, asa i, without systemic disease, without any drug allergy, and without a history of nsaid use in the week before the operation. exclusion criteria: * asa ii or higher, hepatic or renal dysfunction, neuropathic disease, long-term use of nsaids or opioid-derived drugs, a history of allergic reaction to drugs, pain, swelling, inflammation in the head and neck region before the operation, pregnant and breastfeeding with a history of cleft lip and palate and rhinoplasty surgery

Keywords: subspinal le fort osteotomy nasal airway
neuroradiology assesses chiari malformation's impact on airways, cranial base, and sleep disorders in children.

Conditions: Malformation Brain

Summary: the severity of sleep disorders in patients with chiari malformations can vary. the investigators propose to establish a correlation between the severity of sleep-disordered breathing (sdb) and the quantitative neuroradiological data of the airways, cranial base foramina, and posterior cranial fossae

primary objective of the study is the evaluation of sleep-disordered breathing (sdb) in two distinct pediatric populations of patients with chiari malformation type 1 (cm-i) and chiari malformation type 2 (cm-ii). secondary objectives: stratify the presence of sdb into central and obstructive origins in the two study populations. assess the volume of posterior cranial fossae, airway volume, and area of cranial base foramina in both groups. determine the relationships between sdb and morphological-quantitative anomalies associated with cm.

Eligibility criteria:
inclusion criteria: * children (males or females) aged between 3 years and 18 years. * clinical diagnosis of chiari malformation 1 and 2. * presence of informed consent for the initial clinical evaluation. the investigators commit to providing appropriate informational sheets to the parents of the patients (for those included in the study) during the initial clinical evaluation. exclusion criteria: * chiari malformation i and ii associated with neurological diseases or craniofacial malformations. * cranial trauma or cardiac arrest. * administration of centrally acting medications within 2 weeks prior to the study, except for antiepileptic treatment for patients who have had seizures. * associated brain and cranial base tumors. * refusal to sign the informed consent for the initial clinical evaluation. the investigators commit to providing appropriate informational sheets to the parents of the patients (for those included in the study) during the initial clinical evaluation.
evaluation of changes in weight, sleep, and other psycho-behavioural parameters during covid-19 confinement in subjects monitored by the rnpc network

Conditions: Comorbidities; Confinement; Obesity

Summary: during confinement, food intake can become compulsive, physical activity is significantly reduced, sleep is altered with exacerbated anxiety and stress levels and increased family violence. in some at-risk patients, mental health may even deteriorate. the temptation is great for all to take refuge in food or in front of screens. the main elements that can impact weight changes during this period of confinement are stress and anxiety, lack of physical activity, changes in eating habits, sleep disturbance and alcohol consumption. the investigators wish to study the impact of confinement on pre-post confinement weight loss kinetics in adults included in weight reduction programs (rnpc).


Eligibility criteria:
inclusion criteria: * bmi \> 25 kg/m² and/or waist circumference \> 80 cm in women and 94 cm in men * persons registered in the rnpc program * be legally able to give consent after adequate information and submission of the information note * person affiliated to social security exclusion criteria: * being unable to understand, follow objectives and methods due to cognition or language problems subjects listed in articles l1121-5 à l1121-8: pregnant women, feeding and parturient; subject under administrative or judicial control, persons who are protected under the act.
pfu vs. uds in sui

Conditions: Stress Urinary Incontinence (SUI)

Summary: the goal of this observational stury is to test the diagnostic accuracy of pelvic floor ultrasound in evaluating women with stress urinary incontinence compared to the reference standard urodynamic studies. the main question it aims to answer is: is pelvic floor ultrasound as accurate as urodynamic studies in diagnosis of stress urinary incontinence?


Eligibility criteria:
inclusion criteria: * aged ≥ 18 years exclusion criteria: * medical history of neurological disorders, cognitive disorders, dementia, alzheimer's disease, or uncontrolled dm. * surgical history of continence or prolapse procedure. * examination showing anterior or middle compartment decent with pop-q staging greater than stage 1, or urogenital fistula. * known lower urinary tract or genital tract anomalies or tumors.
effects of almonds on glycemia in adults with elevated hemoglobin a1c concentrations

Conditions: Glucose Intolerance; Glucose Metabolism Disorders (Including Diabetes Mellitus)

Summary: this study will examine the effects of regular almond consumption by individuals with elevated hba1c on long-term glycemic control.

globally, it is projected that 418 million people will have impaired glucose tolerance by 2025. in the us, an estimated 34 million americans have diabetes and 88 million, 33% of adults, have pre-diabetes. impaired glucose tolerance is now manifesting in young adults where 20% of those 12-18 years of age have prediabetes. the current prevalence of type 2 diabetes is over 8%, but it is projected that up to a third of americans will develop diabetes in their lifetime. additionally, the total annual cost of diabetes is approximately $327 which accounts for 25% of all us health care costs. moreover, the costs rose 60% from 2007 to 2017 and this trend is continuing. diet is the preferred approach for management for this diet-related chronic disorder. accumulating evidence suggests almond consumption decreases postprandial glycemia and may evoke a second meal effect, especially when they are consumed at breakfast or as an afternoon snack, which may aid in long-term glycemic control. additionally, almond consumption can decrease total and ldl cholesterol, resulting in lower peripheral insulin resistance and cardiometabolic complications from type 2 diabetes mellitus. however, there is mixed evidence on the effects of almond consumption on hba1c, a clinically important endpoint that provides a reliable measure of long-term glycemia and is correlated with risk of complications from diabetes. thus, the investigators hypothesize a beneficial effect of regular almond consumption on long-term glycemic control in individuals with elevated baseline hba1c.

Eligibility criteria:
inclusion criteria: * hba1c \>5.7% * bmi \>20 kg/m\^2 * prefer no use of medications, but if on medication, must have been on a stable dose for 3 months and plan to remain at the same level for the duration of the trial. * healthy, good dentition * no nut allergies * \>4.0 eating events per day * \>=1 low nutrient density snack/d * no allergy to chocolate exclusion criteria: * hba1c within normal range * bmi \<20 kg/m\^2 * nut allergies * smoker * pregnant
registration of idarucizumab for patients with intracranial hemorrhage

Conditions: Intracranial Hemorrhage

Summary: this multicenter, prospective, observational, non-interventional study investigates patients with intracranial hemorrhage under effective anticoagulation with dabigatran or vitamin-k antagonist (vka). routine data will be collected during hospitalization. patients aged 18 years or older under effective therapy with dabigatran and symptomatic intracranial bleeding confirmed by cerebral imaging and treated with idarucizumab will be compared to patients under effective treatment with vka at the time of onset of the intracranial bleeding. ninety-five dabigatran patients who provided written informed consent for data transmission will be included. as control group retrospective and anonymized data of 285 vka patients patients under vka treatment and admitted to ric-ich study centers will be used. for each patient receiving idarucizumab, three patients with intracranial hemorrhage under effective treatment with vka, will be included (retrospective) in the study. in addition, data of vka patients will be transferred from the rasunoa-prime and the "erlanger hirnblutungs-register".


Eligibility criteria:
inclusion criteria (dabigatran-group): * age ≥18 years at enrollment * patients willing and able to provide written informed consent for data transmission (exceptions/special cases for patients who are not legally competent to sign informed consent for data transmission). * patients with primary intracranial hemorrhage as confirmed with ct. * patients under effective anticoagulation treatment with dabigatran at the time of admission (tt\>60 sec. or last intake of medication \<24hours). * patients treated with idarucizumab (2x2.5 g recommended) may still be included the day after the administration of praxbind, or on the following working day if treatment was carried out on the weekend. * inclusion (signed informed consent) as soon as possible after start of symptoms of initial ich event, but before discharge. inclusion criteria (control-group): - patients with intracranial hemorrhage under effective anticoagulation treatment with vka (inr ≥ 1,7) having been initially treated in the past in the study center. exclusion criteria (dabigatran-group): * additional therapy with pcc, apcc or factor vii (in patients under dabigatran). exclusion criteria (all patients): - start of symptoms of initial ich event \> 24 h before admission to hospital.

Keywords: intracranial/intracerebral bleeding stroke transient ischemic attack (tia) myocardial infarction anticoagulation dabigatran idarucizumab vitamin-k antagonists
augmented reality perioperative training and patient satisfaction

Conditions: Anxiety State

Summary: the purpose of this study is to learn more about how augmented reality systems can influence perioperative experience and patient satisfaction.


Eligibility criteria:
inclusion criteria: * all patients 18 years old or greater * patients who have a scheduled ambulatory procedure with university of miami orthopaedic providers. exclusion criteria: * any patient not scheduled for procedures * minors * cognitively incapacitated * prisoners. * have any condition that, in the opinion of the investigator, would compromise the well-being of the patient or the study or prevent the patient from meeting or performing study requirements.
novel support surface to alleviate pressure ulcer

Conditions: Immobility Syndrome; Pressure Ulcer; Pressure Injury

Summary: a prototype support surface has been designed which aims to successfully redistributes the pressures exerted and provides sufficient support to human soft tissue we want to prove the effectiveness of the prototype support surface by enlisting patients in a clinical trial, where we will assess the presence of pressure ulcers, and the ability of the patients to tolerate the support surface, and also measure the pressure over time and compare them to when the patients are using standard mattresses.


Eligibility criteria:
inclusion criteria: 1. patients must be immobile as assessed on the braden scale. 2. patients must require 2 hourly turning 3. age 21-85 exclusion criteria: 1. no existing pressure ulcers 2. no active infections, fever, or medical conditions that require constant medical attention. 3. they must also not have severe incontinence requiring the change of diapers more frequently than 4 hours 4. no significant cognitive impairment 5. pregnant women will be excluded from the study
memantine treatment in alzheimer's disease patients

Conditions: Alzheimer Disease

Summary: the aim of this study is to investigate whether there will be any efficacy difference of memantine treatment in different cognitive severity ad patients stratified with bpsd

planed to enroll a total of 222 patients with mild, moderate or severe ad treated with memantine in 2017-2018 from 15 centers.

Eligibility criteria:
inclusion criteria: 1. probable ad based on the diagnosis criteria of nia-aa guideline (the u.s. national institute on aging and alzheimer's association guideline, mckhann et al, 2011\[8\]; 2. male or female, 50 years and older ; 3. all inpatients or outpatients recruited into this study must meet mmse score ≤24 points, patients with mmse score as 21-24 points will be enrolled into mild group, patients with mmse score as 10-20 points will be enrolled into moderate group, patients with mmse score less than 10 points will be enrolled into severe group. 4. have a reliable caregiver who can accompany the patient to the site to complete the required study procedures; 5. provide the informed consent. exclusion criteria: 1. patients with disturbance of consciousness of any causes; 2. patients with severe aphasia or physical disability who were unable to complete neuropsychological examination; 3. patients with mental illness; 4. patients with a history of alcoholism and drug addiction, or traumatic brain injury, epilepsy, encephalitis, normal-pressure hydrocephalus and other neurological disorders causing cognitive impairment; 5. patients with systemic diseases causing dementia (e.g. liver and kidney insufficiency, endocrine disorders, vitamin deficiency); 6. patients with a history of ischemic or hemorrhagic cerebrovascular diseases, and vascular diseases (stroke foci) as confirmed by imaging examination; 7. subjects who are unwilling or unable to abide by the study requirement.

Keywords: alzheimer disease memantine
a study of telatinib in combination with chemotherapy in subjects with advanced gastric cancer

Conditions: Gastric Cancer

Summary: the objectives of this study are to evaluate the anti-tumor activity, safety, and tolerability of telatinib when used in combination with chemotherapy (capecitabine and cisplatin) as first-line therapy in subjects with advanced gastric cancer. the primary objective is to assess progression free survival (pfs) in subjects receiving telatinib in combination with chemotherapy (capecitabine and cisplatin). the secondary objectives are to assess overall survival, overall response rate, safety and tolerability, pharmacokinetics and biomarkers.


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed adenocarcinoma of the stomach or gastro-esophageal junction with inoperable locally advanced or metastatic disease, not amenable to curative therapy * measurable disease: at least 1 measurable metastatic lesion that has not been irradiated; the lesion will be measured according to recist and be evaluated radiologically within 28 days prior to study entry * ecog performance status of 0 or 1 at study entry * adequate bone marrow, liver and renal function * women of childbearing potential:negative serum pregnancy test within 7 days and must agree to use adequate contraception (barrier method of birth control) prior to study entry, for the duration of study participation and 28 days after the last study drug dosing exclusion criteria: * previous chemotherapy for locally advanced or metastatic gastric cancer:prior neoadjuvant or adjuvant chemotherapy completed at least 6 months prior to study entry is allowed * previous anti-angiogenic therapy: anti vegf or vegfr tyrosine kinase inhibitor such as bevacizumab, sorafenib, sunitinib, azd2171 * previous total platinum dose \>300 mg/m2: total prior platinum dose of ≤300 mg/m2 will be allowed in the adjuvant or neo-adjuvant setting * candidates for curative therapy * clinical or radiographic evidence of brain metastasis * cardiac disease; uncontrolled hypertension; hemorrhage/bleeding events * known or suspected allergy to any component of telatinib, cisplatin or capecitabine * known dihydropyrimidine dehydrogenase (dpd) deficiency * unable to take oral medications that could affect oral intake of capecitabine and telatinib

Keywords: gastric cancer gastro-esophageal cancer ge-junction advanced gastric cancer
cryoprobe transbronchial lung biospy in patients with mechanical ventilation

Conditions: Lung Diseases; Interstitial Disease

Summary: the purpose of this study is to evaluate the the diagnostic yield and safety of transbronchial lung biopsies (tblb) with cryoprobe in patients with mechanical ventilation.


Eligibility criteria:
inclusion criteria: * ≥18 years old * patients with mechanical ventilation. * patients with diffuse lung disease of unknown etiology. * need for confirming/excluding a diagnosis, with therapeutical and prognosis implications. * inform consent signed by family. exclusion criteria: * use of anticoagulant therapy or presence of a coagulation disorder (abnormal platelets counts, international normalized ratio \> 1.5). * comorbidities that could increase the risk of the tblb. * bullous emphysema. * hemoptysis, pneumothorax. * severe respiratory insufficiency requiring peep \>12 cm h2o

Keywords: cryoprobes cryobiopsy transbronchial lung biopsy
a herbal compound for psoriasis

Conditions: Psoriasis; Inflammation; Skin Diseases

Summary: the goal of this interventional clinical trial study is to compare zax.1400.p03 and placebo in psoriasis patients. the main question it aims to answer is: • can treatment with zax.1400.p03 for 3 weeks improve clinical signs of skin in psoriasis patients? participants will be divided into two groups of 52 people. one group will use zax.1400.p03 topically twice daily for 3 weeks and the other group will use placebo topically twice daily for 3 weeks. researchers will compare treatment and placebo groups to see if there is any improvement in the clinical signs of skin caused by psoriasis after treatment with zax.1400.p03 for 3 weeks.


Eligibility criteria:
inclusion criteria: * diagnosis of the disease by a doctor * age range between 18 and 60 years * both sexes (male and female) * having written informed consent to participate in the study * lack of allergy to food and health products * only local tissue involvement and no need to take oral medications * absence of underlying diseases and immune deficiency * absence of pregnancy and breastfeeding * absence of blisters and infection caused by the disease exclusion criteria: * non-consent of the doctor directly responsible for the patient * incidence of drug product allergy * occurrence of symptoms of skin, digestive, liver or kidney diseases * patient\&#39;s lack of consent to continue for any reason

Keywords: skin diseases psoriasis herbal medicines anti-inflammatory natural products inflammation